drugset / Trial / NCT00614822
Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to look for an improvement in progression free survival with the combination of bevacizumab, carboplatin and pemetrexed in patients with newly diagnosed advanced/metastatic non small cell lung cancer. Overall survival and safety will also be assessed.
Timeline
- Start
- 2007-11
- Primary completion
- 2016-08-22
- Completion
- 2016-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |